The vector of anti-EGFR chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human EGFR. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-EGFR antibody linked to a CD4 transmembrane domain and FcεRIγ signaling domains. And the vector product was designed for the immune response cells in preparation of drugs for treatment of malignant tumor and virus infected diseases.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
|VP-CAR-LC198||Lenti-EGFRvIII CAR (scFv-FcεRIγ, RAbDMvIII) Viral Particle|
|VP-CAR-LC196||Lenti-EGFR CAR (scFv-CD28-41BB-CD3ζ) Viral Particle|
|VP-CAR-LC195||Lenti-EGFR CAR (scFv-41BB-CD3ζ) Viral Particle|
|VP-CAR-LC197||Lenti-EGFRvIII CAR (scFv-CD28, RAbDMvIII) Viral Particle|
|CAR-MZ010||Anti-EGFR (Nimotuzumab) h(CD28-CD3ζ) CAR, pCDCAR1|
|CAR-LC377||Anti-EGFR h(CD28-CD3ζ, GITR) Armoured CAR, pCDCAR1|
|VP-CAR-LC836||Lenti-EGFRvIII CAR (scFv-CD3ζ, MR1.1) Viral Particle|
|VP-CAR-LC861||Lenti-EGFRvIII CAR (scFv-41BB-CD3ζ, MR1-1) Viral Particle|
|VP-CAR-LC201||Lenti-EGFRvIII CAR (scFv-CD28-CD3ζ, RAbDMvIII) Viral Particle|
|VP-CAR-LC743||Lenti-EGFR CAR (scFv-41BB-CD3ζ, Nimotuzumab) Viral Particle|
Copyright © 2007 - 2018 Creative Biolabs. All Rights Reserved